Transmission of SARS-CoV-2 Alpha Variant (B.1.1.7) From a BNT162b2-Vaccinated Individual

Article Immunology

Impact of the Coronavirus Disease 2019 (COVID-19) Vaccine on Asymptomatic Infection Among Patients Undergoing Preprocedural COVID-19 Molecular Screening

Aaron J. Tande et al.

Summary: This study found a significant association between vaccination with mRNA-based COVID-19 vaccines and reduced risk of asymptomatic SARS-CoV-2 infection.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019

Maureen Betton et al.

Summary: After COVID-19 infection, levels of IgG antibodies and neutralization activity against SARS-CoV-2 decrease over time, but do not imply loss of neutralizing capacity; A few patients showed negative serological status 6 months post-infection; IgG levels correlate with neutralization and show a stronger correlation for anti-S antibodies.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Matan Levine-Tiefenbrun et al.

Summary: COVID-19 vaccines not only provide protection to individual vaccinees, but may also reduce viral load in breakthrough infections, potentially leading to lower infectiousness and further suppressing virus spread.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers

Shmuel Benenson et al.

Summary: A systematic vaccination program for healthcare workers at Hadassah Medical Center in Israel showed high effectiveness in preventing Covid-19 starting from the second week after the first dose of BNT162b2 vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

Jocelyn Keehner et al.

Summary: A study showed that while 71% of healthcare workers tested positive for SARS-CoV-2 within 2 weeks after receiving the vaccine, the percentage decreased after the second dose.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Public, Environmental & Occupational Health